NasdaqGS - Delayed Quote USD

Halozyme Therapeutics, Inc. (HALO)

53.98
-0.56
(-1.03%)
At close: June 13 at 4:00:01 PM EDT
53.65
-0.33
(-0.61%)
After hours: June 13 at 6:35:17 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. President, CEO & Director 2.34M 4.73M 1963
Ms. Nicole LaBrosse CPA Senior VP & CFO 1.12M 1.04M 1983
Mr. Mark Snyder Esq. Senior VP, General Counsel, Chief Compliance Officer & nd Secretary 1.14M -- 1967
Ms. Cortney Caudill M.B.A. Chief Operations Officer -- -- --
Ms. Tram Bui Head of Investor Relations & Corporate Communications -- -- --
Ms. Amy Marinne Fox Chief Human Resources Officer -- -- --
Mr. Gary Grote Chief Commercial Officer -- -- --
Dr. Christopher Wahl M.B.A., M.D. Chief Business Officer -- -- --
Dr. Charles P. Theuer M.D., Ph.D. Chief Medical Officer -- -- 1964

Halozyme Therapeutics, Inc.

12390 El Camino Real
San Diego, CA 92130
United States
858 794 8889 https://halozyme.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
350

Description

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Corporate Governance

Halozyme Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2025 is 2. The pillar scores are Audit: 5; Board: 1; Shareholder Rights: 3; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 4, 2025 at 10:59 AM UTC - August 8, 2025 at 12:00 PM UTC

Halozyme Therapeutics, Inc. Earnings Date

Recent Events

May 6, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 2, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 21, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 18, 2025 at 12:00 AM UTC

DEF 14A: Proxy Statements

February 18, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

February 13, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 8, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 31, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 6, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers